Albiglutide (Tanzeum): Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โขCommunity protocols detailed below
- โขEvidence level: Anecdotal Reports
- โขBased on 5 community reports
- โขStacking patterns detailed below
Sources
- Reddit r/diabetes|GLP-1 agonist experience discussions including Tanzeum(accessed 2026-02-16)
- Reddit r/Peptides|GLP-1 agonist discussions and comparisons(accessed 2026-02-16)
- Drugs.com|Albiglutide professional patient information and reviews(accessed 2026-02-16)
Community Evidence Overview#
This page documents the community evidence landscape for albiglutide (Tanzeum/Eperzan). This is not clinical evidence and should not be used as medical guidance.
Albiglutide has virtually no community self-experimenter data because it was exclusively a prescription pharmaceutical product that was never available through peptide vendors or compounding pharmacies. Furthermore, GSK discontinued albiglutide worldwide in July 2017, making it entirely unavailable since 2018.
Why There Is No Community Protocol Data#
Unlike many peptides covered on this site, albiglutide was a large recombinant fusion protein (73 kDa) that could only be manufactured through complex biotechnology processes. It was never synthesized by peptide suppliers and was available only through the branded Tanzeum pen device, which required in-device reconstitution before each injection.
Historical Patient Experience#
During its brief time on the market (2014-2017), albiglutide was prescribed to patients with type 2 diabetes as a once-weekly GLP-1 agonist. Limited patient reports from that era indicate:
- Moderate efficacy: Patients generally reported it was less effective for weight loss and glucose control compared to liraglutide
- GI tolerability: Some patients appreciated that albiglutide caused less nausea than other GLP-1 agonists
- Injection site reactions: More common than with liraglutide (6.9% vs 1.2% in head-to-head trials)
- Device complexity: The Tanzeum pen required 15 minutes of reconstitution time, which was a common complaint
Discontinuation Context#
GSK withdrew albiglutide for commercial reasons, not safety concerns. The HARMONY Outcomes trial, published after discontinuation, actually demonstrated meaningful cardiovascular benefits. However, by that time, the market had moved on to more potent alternatives like semaglutide.
Current Alternatives#
Patients and community members interested in GLP-1 receptor agonist therapy should review currently available options:
- Semaglutide - The current market leader
- Liraglutide - Daily injectable GLP-1 agonist
- Tirzepatide - Dual GLP-1/GIP agonist
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Albiglutide (Tanzeum)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.